Abstract

BackgroundTapering of disease modifying antirheumatic drugs (DMARDs) to achieve drug-free remission is a goal for the growing group of rheumatoid arthritis (RA) patients in remission. However, the long-term effects of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
OP0318 TREATMENT TAPERING AND WITHDRAWAL IN RHEUMATOID ARTHRITIS WITH STABLE REMISSION - FINAL ANALYSIS OF THE RETRO STUDY
...
-
, et. al. ...
19 May 2021
AB0263 Agreement between Das28, Acr/eular, Sdai, Cdai and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care
...
Annals of the Rheumatic Diseases | VOL. 75
, et. al. ...
01 Jun 2016
OP0249 Multi-biomarker disease activity and autoantibody status lead to cost effective tapering algorithms in rheumatoid arthritis patients in sustained remission
...
Annals of the Rheumatic Diseases | VOL. 76
, et. al. ...
01 Jun 2017
THU0096 Multi-biomarker disease activity (MBDA) is associated with the progression of structural bone damage in rheumatoid arthritis patients in remission
S Finzel ... J Fogagnolo Cobra
Annals of the Rheumatic Diseases | VOL. 76
S Finzel, et. al.S Finzel ... J Fogagnolo Cobra
01 Jun 2017
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers